Crossject franchit une nouvelle étape clé dans la fabrication de ZEPIZURE®
July 18, 2024 01:30 ET
|
CROSSJECT
Fabrication réussie d’un autre Lot Règlementaire de ZEPIZURE® sur le nouveau site de fabricationUne étape importante qui complète les résultats satisfaisants obtenus avec les lots précédents dans le...
Crossject achieves key ZEPIZURE® manufacturing milestone
July 18, 2024 01:30 ET
|
CROSSJECT
Successful completion of an additional Registration Batch of ZEPIZURE® at new manufacturing siteMilestone complements the satisfying results from previous batches under stability studies, and is...
InflaRx’s GOHIBIC (Vilobelimab) Selected for First BARDA-Sponsored Clinical Trial to Evaluate Novel Host-Directed Therapeutics for Acute Respiratory Distress Syndrome (ARDS)
June 24, 2024 08:02 ET
|
InflaRx N.V.
JENA, Germany, June 24, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, announced...
U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
April 17, 2024 08:00 ET
|
Kaléo
Richmond, Virginia, April 17, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development...
BioAegis Therapeutics Unveils Upcoming Clinical Study of Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
February 27, 2024 15:52 ET
|
BioAegis Therapeutics
BioAegis announces global Phase 2 study of its inflammation regulator protein, gelsolin, for the treatment of Acute Respiratory Distress Syndrome (ARDS).
BioAegis Therapeutics Awarded $20 Million BARDA DRIVe Contract to Advance Gelsolin, an Immune Regulator, as a Treatment for Patients with Acute Respiratory Distress Syndrome (ARDS)
October 16, 2023 14:40 ET
|
BioAegis Therapeutics
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS. NORTH BRUNSWICK, N.J., Oct....
Vir Biotechnology Awarded BARDA Funding to Support Development of Antibody Platform Technologies for Global Infectious Disease Threats
October 03, 2023 07:59 ET
|
Vir Biotechnology, Inc.
Vir Biotechnology Awarded approximately $50 million in BARDA Funding to Support Development of Antibody Platform Technologies for COVID-19
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
July 31, 2023 16:05 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and Development...
BioAegis Leverages Gelsolin’s Broad Therapeutic Applicability by Expanding into Multiple Inflammatory Diseases
January 06, 2023 14:50 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Jan. 06, 2023 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing therapies for inflammatory diseases through a portfolio built around plasma...
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
November 21, 2022 09:00 ET
|
Oncotelic Therapeutics, Inc.
R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...